Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.46 |
| ▸ | RRM1 | P23921 | 1/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | DNM1 | Q05193 | 8/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.39 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.39 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2241685 | 0.98 | RRM1 (0.47) | DPP7RRM1DNM1ALDH1A1TSHR | |
| SCHEMBL6481169 | 0.98 | RRM1 (0.47) | DPP7RRM1DNM1ALDH1A1TSHR | |
| Hydrochloric Acid SCHEMBL6480340 | 0.96 | RRM1 (0.46) | DPP7RRM1DNM1ALDH1A1TSHR | |
| SCHEMBL20757996 | 0.93 | DPP7 (0.39) | DPP7RRM1OPRM1DNM1ALDH1A1 | |
| SCHEMBL9275008 | 0.88 | HTT (0.41) | DPP7RRM1DNM1GNAI3GNAO1 | |
| SCHEMBL10915920 | 0.88 | SLC6A5 (0.47) | RRM1ALDH1A1 | |
| SCHEMBL28100277 | 0.86 | CA12 (0.40) | DPP7DNM1TSHRGNAI3GNAO1 | |
| SCHEMBL28667085 | 0.86 | DNM1 (0.50) | RRM1DNM1ALDH1A1TSHRGNAI3 | |
| SCHEMBL996511 | 0.85 | DNM1 (0.42) | DPP7DNM1ALDH1A1TSHRGNAI3 | |
| SCHEMBL8237997 | 0.85 | OPRM1 (0.43) | OPRM1DNM1ALDH1A1TSHRGNAI3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219949-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | MORPHIC THERAPEUTIC, INC. | 2023-07-13 | — | — | US | disclosed |
| WO-2023076598-A1 | LIPID AMINES | MODERNATX, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219949-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | ITGB6, ITGA6, ITGAV | DPP7 799/4885RRM1 3188/4885OPRM1 1623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.